Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.50 |
| ▸ | NOS1 | P29475 | 1/20 | 0.50 |
| ▸ | NOS2 | P35228 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | PTPRC | P08575 | 2/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | PTPN13 | Q12923 | 1/20 | 0.41 |
| ▸ | TDP2 | O95551 | 2/20 | 0.41 |
| ▸ | NSD2 | O96028 | 2/20 | 0.41 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21681651 | 0.89 | NOS3 (0.47) | NOS3NOS1NOS2TDP1CYP3A4 | |
| SCHEMBL21681652 | 0.85 | NOS3 (0.47) | NOS3NOS1NOS2TDP1CYP3A4 | |
| SCHEMBL6365641 | 0.85 | NOS3 (0.50) | NOS3NOS1NOS2TDP1CYP3A4 | |
| SCHEMBL4160810 | 0.84 | CYP2A6 (0.52) | NOS3NOS1NOS2TDP1CYP3A4 | |
| SCHEMBL28309616 | 0.82 | PTPRC (0.50) | NOS3NOS1NOS2TDP1CYP3A4 | |
| SCHEMBL28996531 | 0.80 | PDK2 (0.42) | NOS3NOS1NOS2TDP1CYP3A4 | |
| SCHEMBL2642064 | 0.80 | NOS3 (0.54) | NOS3NOS1NOS2TDP1CYP3A4 | |
| SCHEMBL16053280 | 0.79 | ADORA2A (0.44) | NOS3NOS1NOS2TDP1CYP3A4 | |
| SCHEMBL19463671 | 0.78 | CD44 (0.50) | NOS3NOS1NOS2TDP1CYP3A4 | |
| SCHEMBL21681654 | 0.78 | NOS3 (0.43) | NOS3NOS1NOS2TDP1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104837832-B | GDF-8 inhibitors | 里格尔药品股份有限公司 | 2019-04-26 | — | — | CN | claimed |
| CN-104837832-A | GDF-8 inhibitors | RIGEL PHARMACEUTICALS INC | 2015-08-12 | — | — | CN | claimed |
| CN-104837832-B | GDF-8 inhibitors | 里格尔药品股份有限公司 | 2019-04-26 | — | — | CN | disclosed |
| CN-106536507-A | 2,3-disubstituted pyridine compounds as TGF-beta inhibitors and methods of use | 里格尔药品股份有限公司 | 2017-03-22 | — | — | CN | disclosed |
| CN-104837832-A | GDF-8 inhibitors | RIGEL PHARMACEUTICALS INC | 2015-08-12 | — | — | CN | disclosed |
| US-20140249135-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2014-09-04 | — | — | US | disclosed |
| CN-103476767-A | Heterocyclic compounds as PI3 kinase inhibitors | HOFFMANN LA ROCHE | 2013-12-25 | — | — | CN | disclosed |
| EP-2132177-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | Novartis Ag (CH) | 2009-12-16 | — | — | EP | disclosed |
| WO-2008106692-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
| CN-1137523-A | Indazoles and use thereof | MITSUBISHI CHEM CORP (JP) | 1996-12-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249135-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | NOS3 2670/4885NOS1 2655/4885NOS2 2597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.